Prediction of cardiac function after weaning from ventricular assist devices  by Liang, Hong et al.
Liang et al Cardiopulmonary Support and PhysiologyPrediction of cardiac function after weaning from
ventricular assist devices
Hong Liang, MD,a Hansheng Lin, MD,b Yuguo Weng, MD,c Michael Dandel, MD,c and Roland Hetzer, MD, PhDc
CS
PFrom the Department of Cardiothoracic
Surgery,a First Affiliated Hospital of Jinan
University, Guangzhou, China; the Depart-
ment of Medical Statistics,b Medical Col-
lege of Jinan University, Guangzhou, Chi-
na; and the Department of Cardiothoracic
and Vascular Surgery,c Deutsches Herzzen-
trum Berlin, Berlin, Germany.
Received for publication April 15, 2005;
revisions received July 30, 2005; accepted
for publication Aug 8, 2005.
Address for reprints: Hong Liang, MD, De-
partment of Cardiothoracic Surgery, First
Affiliated Hospital of Jinan University,
510630 Guangzhou, P.R. China (E-mail:
lianghong58@hotmail.com).
J Thorac Cardiovasc Surg 2005;130:1555-60
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.08.020
TObjective: We analyzed the factors influencing the cardiac function of patients after
weaning from ventricular assist devices and established a prognostic index.
Method: A multivariate analysis was performed using the Cox proportional hazards
model of the clinical parameters of 28 patients with end-stage heart failure before
implantation of a ventricular assist device and directly before weaning from the
device.
Results: After weaning from the ventricular assist devices, 14 of the 28 investigated
patients showed stable cardiac function, and 12 had recurrent heart failure, but only
1 of them died before transplantation or implantation of another ventricular assist
device, and 2 patients died of causes unrelated to heart failure. In addition to left
ventricular ejection fraction, the duration of symptomatic heart failure and left
ventricular intracavitary dimensions in diastole measured before ventricular assist
devices weaning were the major factors influencing cardiac function after weaning.
In the group of patients with heart failure duration less than 3 years, only 2 of 13
cases were recurrent, but in the group with heart failure duration more than 3 years,
10 of 15 cases were recurrent. In 10 patients with 40 to 50 mm left ventricular
intracavitary dimensions in diastole before weaning, only 1 case was recurrent. In 10
patients with 51 to 55 mm left ventricular intracavitary dimensions in diastole, 3
cases were recurrent. In the group with left ventricular intracavitary dimensions in
diastole more than 56 mm, all 8 cases were recurrent. A prognostic index was
calculated using the following formula: prognostic index  10.10  0.208 (heart
failure duration in years)  0.173 (pre-explantation left ventricular intracavitary
dimensions in diastole in millimeters). In the group with a prognostic index less than
0, only 2 of 16 cases were recurrent, and the rate of stable cardiac function in the
51st month after weaning was 83.6%. In the group with a prognostic index greater
than 0, 10 of 12 cases were recurrent, and the rate of stable function in the 57th
month was 0.0%.
Conclusion: In patients with off-pump left ventricular ejection fraction greater than
40%, the duration of symptomatic heart failure and the left ventricular intracavitary
dimensions in diastole measured before weaning yield a useful index to predict
long-term cardiac function after weaning from ventricular assist devices.
The use of mechanical cardiac assist devices as a bridge to cardiac transplan-tation has been broadly reported,1-4 and their beneficial influence on thecardiac function of patients with end-stage heart failure has been estab-
lished.5-11 In March 1995 at the Deutsches Herzzentrum Berlin (German Heart
Institute Berlin), a patient supported with a left ventricular assist device (LVAD) for
160 days showed significant improvement in cardiac function, and the LVAD was
explanted. Cardiac function remained stable after LVAD explantation, and today the
patient is doing well; this was the first case of its kind worldwide. In recent years,
the number of reports of weaning from LVAD support after cardiac recovery has
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cardiac function of the patients several years after weaning.
This study analyzed the clinical data of 28 patients weaned
from mechanical cardiac assist devices and assessed the
influence of pre-explantation clinical parameters on the sta-
tus of cardiac function after weaning. The aim was to find
clinical parameters that can be used to predict stable recov-
ery of cardiac function.
Patients and Methods
Patient Data
Patient data were collected at the Deutsches Herzzentrum Berlin
between March 1995 and January 2003. In this period, 32 patients
were weaned from ventricular assist devices (VADs) after recov-
ery of their cardiac function. There were 30 men and 2 women.
Thirty patients had idiopathic dilated cardiomyopathy (DCM),
without any angiographic evidence of coronary stenoses. Myocar-
dial tissue specimens obtained in these 30 patients before LVAD
implantation also showed no histologic signs of acute myocarditis,
and virologic examinations did not reveal evidence of a virus
infection that could have caused the myocardial disease. Polymer-
ase chain reactions for enterovirus, adenoviruses, and cytomega-
lovirus were negative. In situ hybridization for the same viruses,
and for coxsackievirus, Epstein-Barr virus, and herpes viruses, was
negative in these patients. Only 1 of these 30 patients had a family
history of DCM. The 31st weaned patient had angiographically
proven ischemic cardiomyopathy (ICM), and the 32nd patient had
myocarditis 6 months before LVAD implantation. The patients all
had end-stage heart failure, and their symptoms could not be
controlled by medication. Twenty-six patients received a Novacor
100 LVAD (Baxter Co, Oakland, Calif), 3 patients received a TCI
LVAD (TCI HeartMate, Woburn, Mass), and 3 patients received a
Berlin Heart LVAD, a Berlin Heart INCOR I axial flow pump
(Berlin Heart AG, Berlin Germany), and a biventricular assist
device, respectively. The ventricular assist period ranged from 22
to 794 days (mean, 150  150 days).
During mechanical unloading all patients were treated with
beta-blockers (metoprolol or carvedilol), angiotensin-converting
enzyme inhibitors, aldosterone antagonists (spironolactone), low-
dose loop diuretics (furosemide or torsemide), and digitalis. This
Abbreviations and Acronyms
1-adrenoreceptor  A-1-AAB
DCM  dilated cardiomyopathy
ICM  ischemic cardiomyopathy
LVAD  left ventricular assist device
LVEF  left ventricular ejection fraction
LVIDd  left ventricular intracavitary
dimensions in diastole
LVIDs  left ventricular intracavitary
dimensions in systole
PI  prognostic index
VAD  ventricular assist devicetreatment was also continued in all weaned patients.
1556 The Journal of Thoracic and Cardiovascular Surgery ● DecAt the end of the study, 16 patients had stable cardiac perfor-
mance without any signs of deterioration of echocardiographic
parameters (termed “stable” in the study). Twelve patients had a
recurrence of heart failure (termed “recurrence” in the study) 2 to
57 months (mean, 15.8  19.3 months) after pump explantation
(10 underwent cardiac transplantation, 1 is on the waiting list after
the implantation of another mechanical circulatory support system,
and 1 died of recurrence of heart failure). In addition, 4 patients
died of causes unrelated to heart failure (termed “death” in the
study).
Indications for LVAD implantation were as follows: end-stage
heart disease in patients on the waiting list for cardiac transplan-
tation, deterioration of cardiac function, cardiogenic shock despite
maximal medical therapy including inotropes and intra-aortic bal-
loon pump intervention, and evidence of an early stage of multiple
organ failure with right ventricular function still in a compensatory
period.
Indications for device explantation were as follows: left ven-
tricular ejection fraction (LVEF) increase more than 40% to 45%;
left ventricular intracavitary dimensions in diastole (LVIDd) de-
crease to less than 55 mm; improvement of heart function param-
eters; approximately normal cardiothoracic ratio; and autoantibod-
ies directed against the 1-adrenoreceptor (A-1-AABs) no longer
detectable in the LVAD recipient’s serum.17 The effects of un-
loading on ventricular size, shape, and contraction were evaluated
by weekly transthoracic echocardiographic examinations. If with
the regularly running pump, without any inotropic drug therapy,
the wall motion and diameters of the supported ventricle showed a
tendency to normalization, the pulsatile pumps were set at the
lowest pumping frequency and intermittently stopped for a few
minutes (“off-pump” trial) to evaluate the heart without mechan-
ical support. To prevent thrombus formation inside the pump,
heparin was administrated intravenously before each off-pump
trial. In addition, during the off-pump period the device was
allowed to pump once per minute. In patients with axial flow
pumps, we reduced the rotor speed to a value that results in a zero
net flow over the time of 1 cardiac cycle. In patients with evidence
of relevant cardiac recovery, such off-pump examinations (or trials
with reduced rotor speed in the case of axial pumps) were con-
ducted once per week until the final decision for VAD explantation
was made. Between the off-pump trials the assist pumping rate was
reduced step by step to load the LV gradually. At first the pumping
frequency was reduced by 10 times per minute. If heart size,
LVEF, and left ventricular wall thickness remained stable or
normalized, and the off-pump trial did not reveal relevant alter-
ations in ventricular size, the pumping rate could be reduced by a
further 10 times per minute 1 week later until the lowest possible
pumping rate (50 times/min) was reached. After this, if parameters
of cardiac size and function measured by echocardiography during
repeated off-pump trials in patients with pulsatile pumps or max-
imal reduction of rotor speed in those with axial pumps still
remained nearly normalized, the explantation procedure could be
performed. If left ventricular function could not be improved but
deteriorated during this process, it was necessary to return to the
original LVAD pumping rate. Off-pump echocardiographic data
obtained without any inotropic drug therapy were decisive for the
weaning procedure and LVEF off-pump values of greater than
40% were considered insufficient for reliable LVAD explantation.
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PTo avoid excessive stimulation of the unloaded myocardium
during the process of recovery, dobutamine stress echocardiogra-
phy was not performed during the off-pump trials.
Clinical Parameters
The parameters investigated in the study for their potential prog-
nostic value included the following: the patient’s age, duration of
heart failure, ventricular assist duration, heart rate, echocardio-
graphic parameters (LVEF, LVIDd, left ventricular intracavitary
dimensions in systole [LVIDs], and wall thickness), and hemody-
namic parameters (cardiac index, pulmonary arterial pressure, and
systemic blood pressure), all measured at the time of VAD im-
plantation and before explantation at optimal recovery. Duration of
heart failure was defined as the time period from the first appear-
ance of clinically proved signs and symptoms of heart failure that
necessitated medical treatment up to the date of VAD implanta-
tion. Periods of arrhythmia or electrocardiographic changes before
the first evidence of congestive heart failure were not included in
the calculation of heart failure duration.
Inclusion and Exclusion Criteria
Patients observed for more than 1 month after explantation and
whose clinical data were complete were included in the study.
There were 2 patients who died of causes unrelated to heart failure
at 0.1 and 0.3 months after weaning. The first of these 2 patients
had extensive infection at the LVAD conduit sites before weaning
and died of septic shock; the second died of severe pulmonary
bleeding. One other patient was observed for less than 1 month
after explantation, and another patient’s clinical data were not
complete. These 4 patients were excluded from the study. Finally
we studied 28 cases, comprising 14 patients with stable cardiac
function, 12 patients with heart failure recurrence, and 2 patients
who died of causes unrelated to heart failure (one died of pulmo-
nary embolism and one died of left ventricular bleeding).
Statistical Analysis
Survival time was defined as the period from weaning to the end
of follow-up. Statistical significance of the variables was first
TABLE 1. Univariate analysis by Cox proportional
hazards model
Prognostic factors B P RR 95% CI for RR
Age (y) 0.064 .040 1.067 1.0031.134
HF duration (y) 0.261 .000 1.298 1.1231.500
Assist time (d) 0.004 .025 1.004 1.0001.007
Pre-explantation
LVEF (%) 0.112 .013 0.894 0.8190.977
Pre-explantation
LVIDd (mm) 0.228 .001 1.256 1.1021.431
Pre-explantation
LVIDs (mm) 0.085 .012 1.088 1.0181.163
B, Regression coefficient; RR, exp(B), relative risk; CI, confidence interval;
HF, heart failure; LVEF, left ventricular ejection fraction; LVIDd, left ven-
tricular intracavitary dimensions in diastole; LVIDs, left ventricular intra-
cavitary dimensions in systole.determined by univariate analysis using the Cox proportional
The Journal of Thoracichazards model. The variables that were statistically significant by
univariate analysis were included in a multivariate analysis and
confirmed using the Cox stepwise proportion hazards model. Sur-
vival time was estimated by the Kaplan-Meier method and was
compared between groups divided in accordance with the different
levels of variables that were statistically significant in multivariate
analysis. The predictive model for prognosis was established ac-
cording to the results of multivariate analysis. All analyses were
performed using the SPSS 10.0 software (SPSS Inc, Chicago, Ill).
Results
Univariate Analysis by Cox Proportional
Hazards Model
The prognosis was significantly influenced by 6 of the 13
variables submitted to univariate analysis (Table 1). The
age, duration of heart failure, assist time, pre-explantation
LVIDd, and pre-explantation LVIDs (LVIDd and LVIDs
measured directly before explantation) were seen to be risk
factors, because the risk of recurrences increased with
higher level of the variables (relative risk  1.0, P  .05),
whereas pre-explantation LVEF was predictive of absence
of heart failure recurrence (relative risk 0.894, P .013).
Multivariate Analysis by Cox Proportional
Hazards Model
Multivariate analysis involving the 6 significant factors
determined by univariate analysis identified 2 highly prog-
nostic variables, which were duration of heart failure and
pre-explantation LVIDd (Table 2). The frequency distribu-
tion of duration of heart failure was as follows: 9 cases
shorter than 2 years, 4 cases ranging from 2 to 3 years, 7
cases ranging from 4 to 5 years, and 8 cases ranging from 6
to 13 years. The average duration of heart failure was 4.3 
3.8 (mean  SD) years and 4.0 (median) years.
Survival Analysis
Survival analysis was performed according to the variables
of heart failure duration and pre-explantation LVIDd.
Two groups were distinguished by duration of heart failure:
3 years or less (0-3) and greater than 3 years (4-13). In the 3
years or less group (n  13) there were 2 recurrences and 11
cases of stable cardiac function, whereas in the greater than 3
years group (n  15) there were 10 recurrences, 3 cases of
TABLE 2. Multivariate analysis by Cox proportional
hazards model
Prognostic factors B P RR 95% CI for RR
HF duration (y) 0.208 0.012 1.231 1.0461.450
Pre-explantation
LVIDd (mm) 0.173 0.009 1.189 1.0451.354
B, Regression coefficient; RR, exp(B), relative risk; CI, confidence interval; HF,
heart failure; LVIDd, left ventricular intracavitary dimensions in diastole.stable function, and 2 deaths. Stable function rates were ana-
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months in the 3 years or less group; 50.7% for 9 months,
36.1% for 24 months, and 24.1% for 57 months in the greater
than 3 years group (Figure 1).
Three groups were distinguished by pre-explantation
LVIDd with 1 recurrence, 8 “stable,” and 1 death in 10
cases in the group with less than 50 mm (40-50 mm); 3
recurrences, 6 “stable,” and 1 death in 10 cases in the group
with 51 to 55 mm; recurrence in all 8 cases in the group with
56 to 66 mm (Figure 2).
Figure 2. LVIDd measured before explantation (pre-expl. LVIDd)
and rate of stable cardiac function. LVIDd, Left ventricular intra-
Figure 1. Heart failure duration and stable cardiac function rate.
HF, Heart failure.cavitary dimensions in diastole.
1558 The Journal of Thoracic and Cardiovascular Surgery ● DecPredictive Model for Prognosis
The model was established according to the results of mul-
tivariate analysis involving the 2 variables of heart failure
duration and pre-explantation LVIDd. The value of the
prognostic index (PI) for predicting the survival of individ-
uals was calculated as follows:18
PI 0 1X1 2X2 · · ·  mXm
0(1X1 2X2 · · ·  mXm)
0 is the constant for all the patients, and  and X present
the regression coefficients and variables. The model in this
study was as follows:
1 0.208, X1 4.286, 2 0.173, X2 53.250
00.208 4.286 0.173 53.25010.10
PI   10.10  0.208 (heart failure duration in years) 
0.173 (pre-explantation LVIDd in millimeters).
Two groups were distinguished by the PI: one with PI
below 0 and the other with a PI above 0. In the group with
PI of less than 0 there were 2 recurrences of 16 cases, and
the “stable” rate was 92.9% for 24 months and 83.6% for 51
months. In the group with a PI of more than 0 there was
recurrence in 10 of 12 patients, and the “stable” rate was
66.7% for 6 months, 33.3% for 9 months, 25.0% for 17
months, and 0.0% for 57 months (Figure 3).
Discussion
The indication for VAD implantation was bridging to car-
Figure 3. PI and stable cardiac function rate. PI, Prognosis index.diac transplantation.8 Up to now no attempts have been
ember 2005
Liang et al Cardiopulmonary Support and Physiology
CS
Pmade to use VADs electively with the aim of myocardial
recovery only, and no study has established which patients
in whom end-stage heart disease may achieve myocardial
recovery with VADs. Both in previous reports and in this
study the majority of cases of myocardial recovery with
LVAD were seen in patients with DCM. During the past 9
years, 24% of our patients with DCM supported by VADs
were weaned from mechanical support. At 3 years after
VAD explantation, freedom from recurrent heart failure was
found in only 70% of the weaned patients, so that finally
only 13% of patients with end-stage DCM showed long-
term recovery of cardiac function.
The echocardiographic data were decisive for the wean-
ing procedure. The disappearance of A-1-AABs was help-
ful to optimize the follow-up to select the optimal time for
explantation, after myocardial improvement had reached its
maximum. Of the weaned patients, 96.4% tested positive
for A-1-AABs before VAD implantation, and in 96.3% of
the patients who tested positive, A-1-AABs disappeared
after 3 to 31 weeks of ventricular unloading. However,
between patients with and without heart failure recurrence
during the first 3 years after weaning there were no signif-
icant differences for serum levels of A-1-AABs at the time
of LVAD implantation or for the disappearance time of
A-1-AABs during VAD support.
Implantation of an LVAD is initially almost always as a
bridge to transplantation. The VAD can be explanted only if
cardiac function parameters improve during the assist pe-
riod and it is considered on the basis of comprehensive
clinical assessment and examination that the patient’s own
heart can again tolerate loading and pump blood to the
organs. If cardiac function remains normalized after explan-
tation, the VAD can be considered retrospectively as a
bridge to myocardial recovery.
In the wake of increasing application of VADs, the
reports of improvement and recovery of severely impaired
myocardium during unloading by mechanical cardiac sup-
port enabling weaning from VAD are gradually increasing.
In the follow-up, some of the patients weaned from VAD
required another period of mechanical support or underwent
heart transplantation because of recurrence of heart failure.
The possibility of predicting cardiac function status after
explantation would be extremely valuable, but up until now
this has scarcely been studied because of the small number
of cases. The data collected during this study represent the
largest group of weaned patients in the world from one
center. The study made a retrospective analysis of clinical
parameters to find an index with prognostic value for car-
diac function after weaning. The results can provide refer-
ence values for clinical work.
The study suggests that both the duration of heart failure
and LVIDd measured before VAD weaning have a clear
influence on the stability of cardiac function after weaning.
The Journal of ThoracicThe result is easy to explain clinically. The patients with
long duration of heart failure (3 years) usually have se-
verely impaired myocardium. Serious changes caused by
ventricular remodeling, such as myocardial hypertrophy,
denaturalization, and fibrosis and collagen deposit in the
intracellular matrix, become more serious with prolongation
of the clinical course and repeated episodes of heart failure.
Although the VAD can reverse adverse ventricular remod-
eling, the long clinical course makes this process difficult,
and if the reversal is incomplete, it eventually causes the
recurrence of heart failure after VAD explantation. The
small amount of histologic data obtained from our weaned
patients was insufficient to evaluate their predictive value
for functional cardiac recovery. However, in 10 patients we
evaluated by histomorphometry the amount of fibrosis in
both myocardial samples obtained during LVAD implanta-
tion and biopsy material taken before pump explantation; in
only 1 of these patients was there no reduction of fibrosis
during unloading. Also, regression of myocardial hypertro-
phy during unloading was shown in 9 of these 10 patients.
Explantation of the VAD could be considered only when
LVIDd reached less than 50 mm, but in the process of
weaning, the data may fluctuate. In the study it was shown
that if LVIDd at explantation time was less than 50 mm, the
prognosis would be good; if it was more than 55 mm, the
outcome was worse even if the LVEF was greater than 40%.
This means that the advantageous influence of the VAD on
heart function is reflected also by this echocardiographic
parameter. The more LVIDd approaches the normal range
during circulatory support, the greater the chances are that
the myocardium may completely recover. These results
provide scientific data for the selection of suitable weaning
cases in future clinical work, thus raising the lasting stability
rate of heart function after VAD explantation.
According to our PI, in patients with duration of heart
failure longer than 3 years before VAD implantation, VAD
explantation after functional recovery will be risky as long
as the LVIDd is 55 mm or greater. Although in the past we
did not include the duration of heart failure in our weaning
criteria, our present decision making in patients with signs
of relevant cardiac improvement during ventricular mechan-
ical unloading is markedly influenced by the history of heart
failure. Therefore, in addition to the ventricular ejection
fraction, the PI is also used to evaluate the potential weaning
success.
Although the recurrence of heart failure after VAD ex-
plantation can be treated by implanting another VAD or by
heart transplantation, this not only increases the costs of
medical care but also involves the operative risk of cardiac
transplantation. The predictive model established in this
study was obtained by considering the clinical duration of
heart failure and LVIDd measured before VAD explanta-
tion. The model not only assessed the persistence of stable
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ence framework for the surgeon in selecting device explan-
tation or continuing to wait for transplantation. Myocardial
biopsy might theoretically be more significant for assessing
prognosis, but the process would carry a large risk for
patients, especially at the time of explantation, and for this
reason it is rarely considered for such cases. The parameters
investigated by our study are easily obtained, and the index
will provide valuable reference data for clinical decision
making.
Our data show that there are reliable criteria that indicate
complete and stable cardiac recovery on VADs and also
reliably predict the long-term success of weaning from a
VAD primarily designated as “bridge to transplantation.”
Unfortunately, according to our data it is still not possible to
prospectively identify those patients who would benefit from
elective VAD insertion primarily designed as a “bridge to
myocardial recovery.”
Because all patients with implanted VADs received prac-
tically the same medical therapy during ventricular unload-
ing, no conclusions can be drawn on the contribution of
medication to the process of myocardial recovery.
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